July 8, 2013
Nuvilex Benefits From Shifting Stance on Medical Marijuana
The medical marijuana industry received a major boost recently at the annual United States Conference of Mayors. A unanimous and bipartisan resolution urging the federal government to let states decide for themselves how to handle marijuana policy passed with no speakers rising in opposition. The mayors' conference represents cities with populations of 30,000 or more across the country. This news, on the heels of New Hampshire becoming the final state in New England to approve a medical marijuana program, serves only to benefit entities engaged in medical marijuana research such as Medical Marijuana Sciences, Inc., a subsidiary of Nuvilex, Inc. (OTCQB – NVLX - $0.11 – Spec Buy).
Moreover, a series of independent polls over the past few months indicate a disconnect between most U.S. citizens, physicians, and state legislators, and the federal government regarding medical marijuana. For example, a Fox News poll found that 85% of Americans support medical marijuana usage if prescribed by a doctor and 75% of doctors surveyed in a New England Journal of Medicine poll conveyed similar sentiments. This disconnect is even more apparent if one considers that the U.S. Government, through the Health and Human Services division, was granted a patent (#633507) entitled “Cannabinoids as Antioxidants and Neuroprotectants” that concerns the use of components of medical marijuana for the treatment of neurologic, and other, disorders.
This groundswell of support will eventually lead to the re-classification or downgrade of cannabis from Schedule I of the Controlled Substances Act of 1970 and the greater availability of research grade quantities of marijuana. A change in classification would provide a huge boost to the entire medical marijuana industry as the current category classifies it as a drug with no medicinal value and high potential for abuse, despite the fact that prescription drugs kill more Americans than even hardcore drugs such as heroin and cocaine combined.
As broad, vocal support grows and favorable state legislation continues, the industry is likely to reach a major inflection point as early as 2014. These events will aid in Nuvilex’s formative stages of studying the effect of cannabidiol (CBD)-based cancer treatments (CBD is one of the components of marijuana that are collectively known as cannabinoids) when combined with highly efficacious live-cell encapsulation-based therapies similar to those that have been used for oncologic diseases such as inoperable pancreatic cancer and breast cancer. Nuvilex’s combination CBD-based cancer studies with live-cell encapsulation therapy development might result in bringing a highly effective product and new delivery system for use to treat multiple diseases and conditions, which would be place Nuvilex near the head of the medical marijuana product development class.
You Might Also Like
Senior Analyst: Robert Goldman
The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report, update, article, or note is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.
This publication does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority.
ALL INFORMATION IN THIS REPORT IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.